Phase I study of S 78454 in combination with FOLFOX in patients with digestive cancer

Submission date	Recruitment status No longer recruiting	Prospectively registered	
02/09/2013		Protocol	
Registration date 24/09/2013	Overall study status Completed	Statistical analysis plan	
		[X] Results	
Last Edited	Condition category	[] Individual participant data	
18/04/2018	Cancer		

Plain English summary of protocol

Not provided at time of registration and not expected to be available in the future

Contact information

Type(s)

Scientific

Contact name

Prof Philippe Rougier

Contact details

Hôpital Européen George Pompidou 20 rue Leblanc Paris France 75015

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

CL1-78454-006

Study information

Scientific Title

Phase I dose-escalation study of S 78454 (HDACi) p.o. in combination with FOLFOX in patients with locally advanced or metastatic digestive cancer

Study objectives

To establish the safety profile and the recommended Phase II dose of S 78454 in combination with FOLFOX (folinic acid, fluorouracil, oxaliplatin).

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics approval was obtained before recruitment of the first participants

Study design

International multicentric non-randomised open dose escalation phase I study

Primary study design

Interventional

Secondary study design

Non randomised study

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details to request a patient information sheet

Health condition(s) or problem(s) studied

Locally advanced or metastatic digestive cancer

Interventions

- 1. Capsules containing 20 mg and 100 mg of S 78454 / Oral use / Treatment duration is at the discretion of the investigator
- 2. Concomitant intravenous (i.v.) infusion of FOLFOX / Treatment duration is at the discretion of the investigator

No control group is involved

Intervention Type

Drug

Phase

Phase I

Drug/device/biological/vaccine name(s)

Primary outcome measure

- 1. Dose-limiting toxicities (DLTs) and maximum tolerated doses (MTDs) at the end of cycle 1. Methods used: blood samples, physical examination, electrocardiogram (ECG)
- 2. Safety profile of the combination at each visit

Secondary outcome measures

- 1. Pharmacokinetic evaluation on the cycle 1 by blood sample
- 2. Tumour response evaluation during the study by imagery
- 3. Tumour markers evaluation at each cycle by blood sample

Overall study start date

15/09/2011

Completion date

15/09/2014

Eligibility

Kev inclusion criteria

- 1. Male or female patient aged > or equal to 18 years
- 2. Any histological confirmed measurable or evaluable metastatic colorectal cancer (mCRC) or locally advanced or metastatic gastric or pancreatic cancer with a true primary resistance to FOLFOX
- 3. Ability to swallow oral capsule(s)
- 4. Ability to receive FOLFOX regimen
- 5. Estimated life expectancy > 12 weeks
- 6. Eastern Cooperative Oncology Group (ECOG) performance status < or equal to 1
- 7. Body mass index (BMI) > or equal to 20
- 8. Adequate haematological, renal and hepatic functions

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

60 patients

Key exclusion criteria

- 1. Major surgery within previous 4 weeks
- 2. Chemotherapy (other than FOLFOX) within previous 3 weeks

- 3. Small molecules treatment (tyrosine kinase inhibitor) or antibodies within previous 1 week
- 4. Radiotherapy within previous 4 weeks (except for palliative radiotherapy at localised lesions)
- 5. Pregnant or breastfeeding women, women of childbearing potential or men without effective contraception
- 6. Prior exposure to any histone deacetylase inhibitors (HDACi)
- 7. Neuropathy > grade 1
- 8. Unresolved diarrhea > grade 1
- 9. Concomitant uncontrolled severe systemic disease
- 10. Patient with impaired cardiac function

Date of first enrolment

15/09/2011

Date of final enrolment

15/09/2014

Locations

Countries of recruitment

Belgium

France

Italy

Study participating centre Hôpital Européen George Pompidou

Paris France 75015

Sponsor information

Organisation

Institut de Recherches Internationales Servier (France)

Sponsor details

50 rue Carnot Suresnes France 92284

Sponsor type

Industry

Website

http://www.servier.com/

ROR

https://ror.org/034e7c066

Funder(s)

Funder type

Industry

Funder Name

Institut de Recherches Internationales Servier (France)

Results and Publications

Publication and dissemination plan

Publication plan:

Summary results are published in https://clinicaltrials.servier.com.

Intention to publish date

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study will be available upon request from https://clinicaltrials.servier.com if a Marketing Authorisation has been granted after 1st January 2014.

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Basic results				No	No